Becton Dickinson and Company
BDX
$198.17−0.22%
At close · Nov 3, 2026
Mkt cap
$50.30B
EV/Sales
3.15
P/E ratio
59.9
FY2025 Revenue
$21.84B
EPS (TTM)
$3.31
Gross Margin (FY2025)
45.44%
Profit Margin (FY2025)
7.68%
Beta
0.28
Div yield
2.42%
Sector
Healthcare
What matters now, from SEC filings and analyst ratings
Takeaway
A takeaway appears here once the latest filing has been analyzed.
Latest
BDX earnings
Analysts
RatingsSector-relative grades for valuation, growth, profitability, momentum and revisions
Form 4 trades, last 90 days
Latest SEC filings
No recent SEC filings on file.
Latest stored headlines
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 59.9.
Use this BDX research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full BDX income, balance, and cash tables.
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
BDX is rated Buy (4.37 of 5) and passes 2 of 9 preset screens on the Nov 4, 2026 quant run. Build your own screen
Becton Dickinson and Company (BDX) is a medical instruments & supplies company in the Healthcare sector.
Latest cached Becton Dickinson and Company (BDX) revenue for Sep 30, 2025 was $21.84B. Net income was $1.68B. Statements: https://lician.com/financials/bdx
Becton Dickinson and Company (BDX) trailing P/E is 59.9 on the latest cached fundamentals snapshot.
Becton Dickinson and Company (BDX) market capitalization is $50.30B on the latest cached snapshot.
Becton Dickinson and Company (BDX) cached previous close $198.60; day range $196.24 – $199.17; volume 1,956,404. Session quote: https://lician.com/quote/bdx
Becton Dickinson and Company (BDX) latest cached earnings event is "BDX earnings" on Aug 6, 2026. Earnings calendar: https://lician.com/earnings
SEC filings · latest fiscal year FY2025
Free shows the newest 2 years. FY2022–FY2023 on Pro
+8.2%
Revenue growth year over year
10-Q results and the earnings calendar
Revenue and EPS are GAAP diluted from the 10-Q. Beat or miss compares the calendar's actual with its estimate on the same basis (adj.), or revenue with the revenue estimate.
Institutional holders from SEC 13F filings
BDX earnings call
Call time not announced yet · report Thu, Nov 5
Company investor site: bd.com. IR page from the company's last earnings release (Aug 6, 2026).
Quant rating
MetricsHow it works4.37Buy
Lician Quant Grades · vs 548 Healthcare stocks · Nov 4, 2026
Next earnings
Thu, Nov 5Confirmed
Before the open · tomorrow
EPS est. $4.06
Earnings
Short interest
3.12%of float
5.5 days to cover
−8.9% vs prior report
FINRA · settled Oct 15Short data
52-week range
$135.29$200.42
Price $198.17 · 1.1% below high
Low $135.29, high $200.42, last $198.17.Daily closesChart
Get alerted when BDX confirms or moves its Nov 5 report
Free account, no card. Earnings date alerts are free for every stock on your watchlist; beat/miss results come with Pro.